Synta Announces Presentations At The 2012 American Society For Clinical Oncology (ASCO) Annual Meeting

Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced scheduled presentations at the 2012 American Society for Clinical Oncology (ASCO) Annual Meeting June 1-5 at the McCormick Place in Chicago.

GALAXY – Trial design

“ The GALAXY Trial™ (NCT01348126): A Randomized 2b/3 Study of Ganetespib (STA-9090) in Combination with Docetaxel versus Docetaxel Alone in Subjects with Stage IIIB or IV NSCLC.” (Abstract: TPS7613^) – June 2, 1:15 pm - 5:15 pm CT; General Poster Session- Developmental Therapeutics Lung Cancer - Non-small Cell Metastatic. Poster Board: 53G, S Hall A2.

Presenter: Glenwood D. Goss, MD, FCPSA, FRCPC - Ottawa Hospital Cancer Centre Ottawa, Ontario

Updated Phase 1 results – Ganetespib/docetaxel combination in solid tumors

“ A Phase 1 and Pharmacokinetic Study of Ganetespib (STA-9090), a Heat Shock Protein 90 Inhibitor, in Combination with Docetaxel in Subjects with Advanced Solid Tumor Malignancies.” (Abstract: 3094) – June 4, 8:00 a.m. – 12:00 pm CT; General Poster Session- Developmental Therapeutics. Poster Board: 19D, S Hall A2.

Presenter: John S. Kauh, M.D. - Winship Cancer Institute of Emory University, Atlanta, GA

Ganetespib activity in ALK- and ROS-driven cancer models

" Preclinical Activity of the Hsp90 Inhibitor, Ganetespib, in ALK- and ROS1-Driven Cancers.” (Abstract #3090) – June 4, 8:00 a.m. – 12:00 pm CT; General Poster Session- Developmental Therapeutics - Experimental Therapeutics. Poster Board: 18H, S Hall A2.

Presenter: David Proia, Ph.D. – Synta Pharmaceuticals Corp.

Ocular toxicity profiles of Hsp90 inhibitors

" Associating Retinal Drug Exposure and Retention with the Ocular Toxicity Profiles of Hsp90 Inhibitors." (Abstract #3086) – June 4, 8:00 a.m. – 12:00 pm CT; General Poster Session- Developmental Therapeutics. Poster Board: 18D, S Hall A2.

Presenter: Dan Zhou, M.D., M.M. – Synta Pharmaceuticals Corp.

About Ganetespib

Ganetespib is a potent, small-molecule inhibitor of heat shock protein 90 (Hsp90). Hsp90 is a molecular chaperone required for the proper folding and activation of many cancer-promoting proteins, and is recognized as a key facilitator of cancer cell growth and survival. In preclinical experiments, ganetespib has shown activity in multiple tumor models both as a single agent and in combination with certain widely used cancer agents. Ganetespib is currently being evaluated in a broad range of cancer clinical trials. In these trials, ganetespib has shown clinical activity in heavily pretreated patients and has been well tolerated to date with no evidence of severe liver or common ocular toxicities seen with other Hsp90 inhibitors. The most common adverse event seen to date has been transient, mild or moderate diarrhea, which has been manageable with standard supportive care. Information on clinical trials with ganetespib can be found at www.clinicaltrials.gov.

About Synta Pharmaceuticals

Synta Pharmaceuticals Corp. is a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to extend and enhance the lives of patients with severe medical conditions, including cancer and chronic inflammatory diseases. Synta has a unique chemical compound library, an integrated discovery engine, and a diverse pipeline of clinical- and preclinical-stage drug candidates with distinct mechanisms of action and novel chemical structures. All Synta drug candidates were invented by Synta scientists using our compound library and discovery capabilities. For more information, please visit www.syntapharma.com.

1 2 Next › Last »